Cargando…
C-terminal–modified LY2510924: a versatile scaffold for targeting C-X-C chemokine receptor type 4
C-X-C chemokine receptor type 4 (CXCR4) constitutes a promising target for tumor diagnosis and therapy. Herein, we evaluate a new 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-conjugated CXCR4 antagonist derived from LY2510924, FRM001, and its metal complexes as CXCR4-targeting pro...
Autores principales: | Suzuki, Kentaro, Ui, Takashi, Nagano, Akio, Hino, Akihiro, Arano, Yasushi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814797/ https://www.ncbi.nlm.nih.gov/pubmed/31653903 http://dx.doi.org/10.1038/s41598-019-51754-0 |
Ejemplares similares
-
Population Pharmacokinetic and Pharmacodynamic Modeling of LY2510924 in Patients With Advanced Cancer
por: Bihorel, S, et al.
Publicado: (2017) -
Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587
por: Peng, Sheng-Bin, et al.
Publicado: (2017) -
Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors
por: O'Hara, Mark H., et al.
Publicado: (2020) -
Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
por: Boddu, Prajwal, et al.
Publicado: (2018) -
Occurrences and Functions of Ly6C(hi) and Ly6C(lo) Macrophages in Health and Disease
por: Li, Yuan-hui, et al.
Publicado: (2022)